who paed cardiac failure review

7/31/2019 WHO Paed Cardiac Failure Review

1/31

17th ExpertCommittee on the Selection andUseof EssentialMedicinesGeneva,March 2009

Cardiac Failure in Children

Sean Beggs1

Angus Thompson2Rose Nash2

Anna Tompson2

Gregory Peterson2

1. Paediatric Department, Royal Hobart Hospital and University of

Tasmania

2. UMORE, School of Pharmacy, University of Tasmania

September 2008


2/31

Contents

Summary_________________________________________________________________________________3

Introduction______________________________________________________________________________5Burden of disease from cardiac failure in children ____________________________________________6What medicines are essential for the treatment of cardiac failure in children? ____________________8

Current status of the EMLcand guidelines____________________________________________8Diuretics__________________________________________________________________________9Digoxin__________________________________________________________________________11Angiotensin converting enzyme inhibitors (ACE inhibitors) ___________________________13Angiotensin receptor blockers (ARBs)_______________________________________________16Aldosterone antagonists ___________________________________________________________17Betablockers_____________________________________________________________________18Antiarryhtmic drugs_______________________________________________________________19Inotropes_________________________________________________________________________19

Other therapies___________________________________________________________________19Discussion ______________________________________________________________________________19

Treatment________________________________________________________________________19Unanswered Questions____________________________________________________________27

Conclusion______________________________________________________________________________21Appendix 1: Search Strategy_______________________________________________________________22References_______________________________________________________________________________35


3/31

SummaryIn children, cardiac failure is most often caused by congenital heart disease and

cardiomyopathy. These causes are significantly different from those usually responsible for

the condition in adults, which include coronary artery disease and hypertension.

Literature searches were undertaken using a variety of search engines including PubMed,the Cochrane Library, BMJ Clinical Evidence and the National Guideline Clearinghouse to

identify evidence for the management of cardiac failure. There is a large amount of research

published on the management of heart failure in adults, which has given rise to significant

changes in management in the last decade. However, there are far fewer studies in children

and those which do exist are often small, retrospective and use a diverse range of measures

to assess efficacy.

As a result, the management of cardiac failure in children has largely evolved based on

clinical experience and the application of adult data, supported by the more limited

paediatric literature. Given the significant differences in aetiology of heart failure betweenthe adult and paediatric populations, this is not ideal. However, clinical experience in

paediatrics with the drugs which have been proven to be beneficial in adults provides some

reassurance that the outcomes may be similarly beneficial.

On this basis, it is recommended that the EMLc is expanded to include additional treatment

options for children with cardiac failure, namely an ACE inhibitor and a betablocker.

In the case of ACE inhibitors, the two supported by the greatest paediatric data are captopril

and enalapril. The former has the advantage of greater stability in liquid formulation and the

latter the advantage of requiring less frequent dosing. It should be noted that there is very

limited published data on the paediatric use of those ACE inhibitors most widely used inadults (such as ramipril, lisinopril and perindopril) and none at all in children with heart

failure. Captopril is proposed for addition to the EMLc, as the representative of the ACE

inhibitor group.

In terms of betablockers, the vast majority of evidence in paediatric cardiac failure is with

carvedilol, which is supported by findings from the trials in adults, where it has been

consistently shown to improve outcomes. Carvedilol should therefore be considered the

betablocker of choice in children with cardiac failure and be considered for inclusion on the

EMLc.

The EMLc already includes a number of drugs used in management of cardiac failure inchildren: frusemide, digoxin, spironolactone and dopamine. Although this review considers

it appropriate to retain these four drugs in the EMLc at the current time, it should be noted

that there is a lack of robust research to support the use of these drugs in the paediatric heart

failure population; in particular digoxin, which appears to remain widely used based solely

on longstanding clinical practice.

Although Angiotensin Receptor Blockers (ARBs) are increasingly used in cardiac failure in

adults, especially where there is intolerance to ACE inhibitors, there is no published

evidence supporting their use in children with the condition. Consequently, it is not

considered appropriate to include an ARB in the EMLc at the current time.

Whilst there is data emerging for a range of other therapy options, this is not sufficiently

robust to warrant their inclusion in the EMLc at the current time


4/31

By adding an ACE inhibitor and betablocker to the EMLc, a greater number of those

children worldwide who have cardiac failure should be able to benefit from improved

outcomes.

There is also a pressing need for improved research into the treatments used in paediatric

cardiac failure, as well as extension of product licenses where appropriate; and greater

availability and standardisation of the formulations required for effective delivery of thesetreatments.

In addition to work around the drugs used to treat heart failure, continued efforts to reduce

the burden of malnutrition and malaria which may exacerbate heart failure through anaemia

and other causes; are essential in developing nations.

Introduction

The subcommittee of the Expert Committee on the Selection and Use of Essential Medicines

identified Cardiac Failure as an area where more information was required to inform their

decision for future meetings.

The aim of this review was to address the following questions that came out of the initial

meeting.

1. What is the burden of disease from cardiac failure in children under 12years of age?

2. What medicines are essential for treatment?3. Are these already on the EMLc in an appropriate dosage form and

strength?

4. If not, what needs to be added?In order to address the above questions, a search and review of existing literature was

undertaken, as outlined in Appendix 1.

Burden of disease from cardiac failure in children

Cardiac failure is a clinical syndrome where the heart is unable to provide the output

required to meet the metabolic demands of the body; however, the causes and mechanisms

of cardiac failure are significantly different between adults and children (1).

In adults, cardiac failure usually involves failure of the left ventricle, with the most common

causes in developed nations being coronary artery disease; hypertensioninduced cardiac

stress, arrhythmias and valvular disease. In developing nations, it has been reported that

other causes are frequently implicated, including rheumatic heart disease (20.1%) and

cardiomyopathy (16.8%) (2).

In children, the causes of cardiac failure are significantly different and many cases are due to

congenital malformations, such as lefttoright shunts. In these patients the function of both

the right and the left ventricles will be affected and these children suffer from highoutput

cardiac failure. Other significant causes of heart failure in children are cardiomyopathy (3)

and anthracycline toxicity, which lead to low output cardiac failure. In developing nations,many cases are caused or exacerbated by anaemia, often secondary to malaria and


5/31

developed countries may be at risk of heart failure linked with hypocalcaemia and vitamin D

deficiency (5).

There is also a much higher proportion of children with heart failure who have undergone

cardiac procedures (61.4%) compared to adults with heart failure (0.28%); this reflects the

incidence of congenital defects, frequent surgical intervention to correct this, and the

subsequent and eventual deterioration in cardiac function that is seen in many of thesechildren.

Accurately estimating the incidence of cardiac failure in children is problematic. Congenital

heart disease occurs in around 8 per 1000 live births; however, many of these children

receive early surgical intervention and it has been estimated that the yearly incidence of

heart failure as a result of congenital defects is between 1 and 2 per 1000 live births (6). As a

result, cardiomyopathy contributes significantly to the number of paediatric patients who

present with the symptoms of cardiac failure. Data from the United States (7) and Australia

(8) suggests the incidence of cardiomyopathy to be 1.13 per 100,000 and 1.24 per 100,000,

respectively. Nonetheless, it should be recognised that not all patients with cardiomyopathyhave heart failure, which is supported by data from the UK (9), which reports the incidence

of heart failure assessed at first presentation to hospital to be around 0.87 per 100,000. Data

from Nigeria suggests that 7.02% of emergency paediatric admissions to a tertiary centre

hospital are for cardiac failure, with over 90% of cases being from lower socioeconomic

groups (4). In general the prognosis for children with cardiomyopathy is poor, with 5year

mortality reported at around 80% (10) and many cases progress to requiring heart

transplantation when drug therapy proves insufficient.

What medicines are essential for the treatment of cardiac failure

in children?

Current status of the EMLc and guidelinesThe October 2007 cardiovascular medicines section of the WHO Essential Medicines List for

Children (EMLc) contains digoxin, frusemide, spironolactone and, on the complementary

list, dopamine. Clinical practice in the management of cardiac failure in children uses a

wider range of medicines than those currently on the EMLc; consequently, the subcommittee requested this review.

Management of cardiac failure in adults is covered by a number of national guidelines (1115). In contrast, although there are many reviews of the management of cardiac failure inchildren (6, 1623), there are no national or international guidelines to steer consistent

evidencebased practice.

The approach to the management of cardiac failure in children has consequently developed

from a combination of clinical experience, small scale studies in paediatric populations and

the application of adult trial data to the paediatric population. Given the significant

differences in the causes of cardiac failure between the adult and paediatric populations,

caution is required when applying evidence in this way and it may be misleading (6).

Most of the drugs used in paediatric cardiac failure are not licensed for use in children and

are not routinely available in suitable formulations, which introduces additional

complications in terms of practical dose administration and potential bioavailability and

bioequivalence (24).


6/31

This review seeks to summarise the evidence which is available and provide a basis on

which the committee can formulate guidance on the management of cardiac failure in

children, supported by an appropriate EMLc.

Diuretics

Rational for use of Diuretics:

Diuretics have two main effects which may be beneficial in heart failure:

increased water loss increased sodium loss

Diuretics have been widely used in cardiac failure in both adults and children for many

years, providing rapid relief from the symptoms of fluid overload; however, the effects of

diuretics on disease progression and survival have been unclear.

Most patients with heart failure who require diuretic therapy are treated with loop diuretics,

rather than thiazides, as they are more powerful agents (11). However, the use of loopdiuretics has been questioned on the basis of the lack of randomised clinical trials and the

potential for undesirable effects on intracellular and extracellular magnesium and calcium

ion concentrations, and thiamine deficiency (23, 25).

A Cochrane systematic review specifically considered the risks and benefits of diuretics in

heart failure and found a limited number of studies which met their criteria. Based on 14

trials, with 525 participants, this review drew the conclusion that diuretics appeared to

reduce risk of death and deterioration of cardiac failure compared to placebo, and improved

exercise capacity when compared to other active treatments (26).

One review of paediatric heart failure has specifically laid out a treatment pathway, which

positions diuretics, including frusemide, as a first step (alongside digoxin) (20). Consistent

with this approach, many of the trials looking at ACE inhibitors and betablockers in cardiac

failure in children have reported their use was in addition to standard therapy, which where

specified, has without exception included diuretics, particularly frusemide

Of the available loop diuretics, frusemide is the most widely used in cardiac failure and is

already included in the EMLc, in a range of presentations. Bumetanide is also available and

used in paediatrics, although there is limited published data on the use of this alternative

loop diuretic in heart failure amongst children (27).

Research in adults with heart failure has suggested that torasemide, a longeracting loop

diuretic, is at least as effective as frusemide (28). More recently, a small study specifically in

children with cardiac failure concluded that torasemide was safe and effective in this group,

with significant improvements in heart failure index measurements amongst newlydiagnosed patients (29).

As highlighted above, the loop diuretics have been the most widely used in heart failure,

although in some situations other types of diuretics have a role. In adult patients with mild

heart failure, thiazide diuretics may be effective as monotherapy. In refractory oedema,

sometimes referred to as braking, there is an apparent decrease in the urine volume

produced by standard diuretic therapy and this occurs in children and infants, as well as

adults (30). In this situation combinations of drugs with different sites of action have beenused, most commonly a thiazide (or thiazidetype) diuretic with a loop diuretic. One small

study in children with frusemideresistant oedema, reported that the combination of


7/31

frusemide with metolazone (a thiaziderelated diuretic) produced significant improvements

in urinary volume and sodium excretion (31) in the absence of chronic renal insufficiency. A

review of the same approach in adults reported that there were few studies, but based on

these and an additional observational study, concluded that use of low dose metolazone

(5mg) added to loop diuretics is effective and relatively safe for adult outpatients with

refractory heart failure (32), although significant electrolyte disturbances were reported.

Hydrochlorothiazide is included on the essential medicines list for adults as an option in

both hypertension and heart failure. A review by the European Medicines Evaluation

Agency (EMEA) has identified a need for the indications for hydrochlorothiazide, including

heart failure, to be extended to all age groups, as well as the development of an age appropriate formulation (33). The same review makes no reference to metolazone.

The role of those diuretics which are aldosterone antagonists is discussed separately, as their

application in heart failure is different to that of the thiazide and loop diuretics.

Based on the existing inclusion of frusemide in the EMLc, its widespread use, availability in

formulations suitable for paediatric administration and the lack of any compelling datashowing specific advantages of other loop diuretics, it is considered appropriate to retain

frusemide as the loop diuretic of choice in the EMLc.

The need for an additional diuretic, of the thiazide (or thiazidetype), is less clear. Whilst the

limited evidence supports use of metolazone, the EMEA appears to consider

hydrochlorothiazide as the preferred option. At this point in time there is insufficient

evidence to argue for their inclusion on the EMLc.

Digoxin

Rational for use of Digoxin:Digoxin has a number of effects which may be beneficial in heart failure:

inotropic effects slowed heart rate, improving balance of oxygen supply and demand inhibition of sympathetic nervous system inhibition of renin release

Cardiac glycosides have been used in the management of cardiac failure for over 200 years.

Whilst digoxin and related drugs are still considered to have a role in the presence of atrial

fibrillation, their place in the therapy of patients with cardiac failure without atrial

fibrillation has been increasingly questioned, particularly given the significant changes in

heart failure management over the last 20 years.

There is a dearth of research published evaluating the role of digoxin in children with

cardiac failure. However it is notable that many of the trials looking at other therapies in

paediatric cardiac failure have referred to standard treatment, which has almost without

exception included digoxin, indicating that it remains widely used, despite the lack of trial

evidence.

A Cochrane systematic review sought to clarify the evidence in adults with heart failure who

were in sinus rhythm and identified thirteen articles which met their criteria and reported

endpoints including mortality, clinical status and hospitalisation. This review concluded that

the data shows no evidence of a difference in mortality between treatment and control

groups, but that digitalis therapy is associated with a lower rate of hospitalisation and of


8/31

There is no equivalent systematic review looking at the role of digoxin in paediatric cardiac

failure and the significance of the conclusions of the Cochrane review for children is unclear,

especially given the differing aetiology. Those reviews and discussions which have focussed

on paediatric cardiac failure vary in their assessments, with some suggesting use of digoxin

is controversial (22) whilst others position it as a first line treatment alongside diuretics (20).

At a time when betablockers are being more widely used, it is important to note that aclinically significant interaction has been documented between carvedilol and digoxin. This

can result in significant increases in digoxin levels, which necessitates a reduction in the

digoxin dose to avoid the risk of digoxin toxicity (35). It would be prudent to highlight this in

any guidance on management of heart failure where these two drugs may be given

concurrently.

Digoxin in a range of formulations is already included in the EMLc and, given its application

in other indications, it is considered appropriate for it to be retained. However, the specific

inclusion of digoxin for cardiac failure would appear to be based on long established clinical

practice rather than on robust evidence and this should be noted by the committee.

Angiotensin Converting Enzyme Inhibitors (ACE inhibitors)

Rational for use of angiotensin converting enzyme (ACE) inhibitors:

ACE inhibitors reduce the effects that result from the activation of the renin angiotensinaldosterone

(RAA) system which often occurs in heart failure. The beneficial effects of ACE inhibitors in heart

failure may therefore include:

reduced Angiotensin II mediated vasoconstriction reduced Angiotensin II mediated potentiation of sympathetic nervous system activity reduced Angiotensin II mediated aldosterone release and therefore

o reduced sodium and water retentiono reduced myocardial fibrosiso reduced inhibition of nitric oxide release

reduced breakdown of vasodilatory bradykinin

A number of angiotension converting enzyme inhibitors have been studied in large

randomised trials in the management of cardiac failure in adults, with generally consistent

findings of reduced symptoms, morbidity and mortality. Of those studied enalapril,

lisinopril and ramipril have the greatest weight of evidence in heart failure. There is no data

directly comparing the different ACE inhibitors on which any conclusions about the

superiority of one over another can be drawn. Based on studies and reviews of various ACEinhibitors in other conditions, such as postMI (36), hypertension (37, 38), stroke (39),

diabetes (40) and renal disease (41), and the generally favourable outcomes seen, there has

been a tendency to consider that ACE inhibitors exhibit a class effect. Consequently, other

drugs in the group such as perindopril, captopril and trandolapril are also widely used in

adults.

In children with cardiac failure, the ACE inhibitors which have been most studied are

captopril and enalapril, with more modest data for cilazapril. Whilst there is some data

supporting ramipril and lisinopril in children with hypertension (42, 43), there is no

published data on the use of these drugs in children with heart failure and no published

studies on the use of perindopril in children for any indication.


9/31

The key studies on the use of ACE Inhibitors in children with cardiac failure are summarised

in Table 1. It should be noted that many of the studies have been retrospective and assessed

surrogate markers for clinical outcomes.

In common with experiences in adults, a number of children treated with ACE inhibitors

experienced deterioration in renal function and hypotension. In many cases discontinuation

of the ACE inhibitor or reduction in dose was effective in reducing these problems; however,some of the studies reported renal failure and death in a small number of cases. It should,

however, be noted that as many of the patients included in these reports were already

significantly haemodynamically compromised, the exact role of the ACE inhibitor in the

development of these adverse outcomes is unclear. Other adverse effects were reported in

one of these trials and included one case of neutropaenia and one case of cough, both of

which resolved on discontinuation of the ACE inhibitor (44).

On the basis of the available data, a recent review of use in paediatric practice concluded that

myocardial dysfunction should be treated with ACE inhibitors, mildmoderate valvular

insufficiency is effectively treated with ACE inhibitors and large left to right shunts should

be surgically treated, unless surgery is not appropriate, when an ACE inhibitor should beused (45).

There is currently not an ACE inhibitor included on the EMLc; based on the evidence and

current clinical opinion, this needs to be addressed. Enalapril and captopril account for the

majority of the evidence from studies in children; consequently, any ACE inhibitor to be

included in the EMLc would most rationally be one of these two.

A recent review has concluded that the lack of definitive data comparing individual drugs

makes it inappropriate to recommend a specific ACE inhibitor for use in children (45);

however, for practical purposes the inclusion of one ACE inhibitor on the EMLc would be

desirable. In the absence of compelling clinical reasons to select a specific ACE inhibitor, it isappropriate to consider other factors which may affect the practical administration of these

drugs. It is recognised that the preparation of enalapril in a liquid formulation is challenging,

whereas in some countries a licensed liquid formulation of captopril is available, to

supplement the tablet formulation which would be appropriate for older children. However,

the shorter duration of action of captopril necessitates more frequent administration, usually

three times per day compared to once or twice per day for enalapril and the latter is already

included in the essential medicines list for adults. The relative merits of these factors needs to

be carefully considered in any decision which is made regarding inclusion of an ACE

inhibitor in the EMLc.


10/31

Table 1. Summary of studies on ACE inhibitors in Paediatric Cardiac Failure and related conditions

(DCM=dilated cardiomyopathy, LVD=left ventricular dysfunction, VSD=ventricular septal defect)

Study Population treated

with ACE inhibitor

ACE Inhibitor used Key findings and comments

(46) 27 with DCM Captopril

(0.93.9mg/kg/day)

Significantly improved survival over first two years, trend towards this continued

thereafter.

(47) 18 LVD post

doxorubicin

Enalapril

(mean 18mg/day)

Left ventricular function improved over the first six years, deteriorating between 6

and 10 years.

(48) 12 with DCM Captopril Improvements in haemodynamic effects.

(44) 63 with LVD

(congenital & acquired)

Enalapril

(mean 0.3mg/kg/day)

58% of patients improved, 30% had no improvement and 12% had sideeffects.

3 patients died with cardiac / renal failure.

(49) 8 with CM and HF Enalapril

(0.5mg/kg/day)

Persistent clinical improvement after one year, with decreased heart size reported.

(50) 6 with VSD and HF Enalapril

(0.120.43mg/kg/day)

Clinical improvements in all patients, improvements in body weight and feeding

(51) 8 with VSD and HF Enalapril

(0.16mg/kg/day)

Enalaprilat

Clinically effective and well tolerated in all patients

(52) 20 with left to right

shunts and HF

Captopril

(0.92.5mg/kg/day)

Clinical improvement in most patients, four developed renal failure or hypotension.

Improvements in weight gain and respiration rate reported.

(53) 20 with aortic

regurgitation

Captopril(11.5mg/kg/day)

Left ventricular dilatation and hypertrophy were reversed.

(54) 13 with DCM and postsurgical

Cilazapril

(0.04mg/kg/day)

Treatment reduced left ventricular afterload and increased LV shortening.


11/31

Angiotensin Receptor Blockers (ARBs)

Rational for use of Angiotensin Receptor Blockers (ARBs):

Angiotensin Receptor Blockers (ARBs) reduce some of the effects that result from the activation of the reninangiotensinaldosterone (RAA) system which often occurs in heart failure. The beneficial effects ARBs in heart

failure may therefore include:

reduced Angiotensin II mediated vasoconstriction reduced Angiotensin II mediated potentiation of sympathetic nervous system activity reduced Angiotensin II mediated aldosterone release and therefore

o reduced sodium and water retentiono reduced myocardial fibrosiso reduced inhibition of nitric oxide release

Three ARBs have been studied in adults with heart failure candesartan, losartan and valsartan.

Although an initial small trial with losartan was encouraging, a subsequent larger study failed to

confirm that it was as effective as an ACE inhibitor (55). Candesartan (56) and valsartan (57) have,however, been shown in subsequent trials to provide beneficial outcomes in adults with heart failure;

although they have not been shown to be superior to ACE inhibitors. As regards the inclusion of heart

failure as a licensed indication for these two ARBs, there is international variation.

In view of the more established evidence base for ACE inhibitors in cardiac failure and the lower cost

of the latter, some guidelines for adult heart failure recommend that ARBs are only used as an

alternative to ACE inhibitors where patients are intolerant to these, usually as a result of a persistent

dry cough (11).

There is very little published data on the use of ARBs in children. The pharmacokinetics of irbesartan

in hypertensive children have been reported (58), as has the effectiveness of losartan in hypertensive

children (59); however, no published studies specifically on the use of ARBs in children with cardiac

failure were identified. It should be noted that heart failure data for these two specific ARBs is either

lacking or suboptimal.

A recent review has concluded that as there is no efficacy data on ARBs in children with heart failure,

they should only be used where there is intolerance to an ACE inhibitor (21), which is in line with

general practice in adults. In line with this, it is not considered appropriate to make recommendations

to add an ARB to the EMLc at the current time or to include an ARB in guidance on management of

cardiac failure in children.

Aldosterone antagonists

Rationale for use of aldosterone antagonists:

Aldosterone antagonists reduce some of the effects that result from the activation of the renin angiotensinaldosterone (RAA) system which often occurs in heart failure. The beneficial effects of aldosterone antagonists in

heart failure may therefore include:

Reduced sodium retention Reduced water retention Reduced myocardial fibrosis


12/31

Reduced inhibition of nitric oxide release Slowed heart rate, improving balance of oxygen supply and demand Reduced myocardial apoptosis and fibrosis Antiarrhythmic effects

There has been renewed interest in the role of aldosterone antagonists in heart failure following

research in adults demonstrating that the addition of spironolactone at low doses (25mg per day) to

standard care was beneficial in terms of symptoms and hospital admissions (60). Use of

spironolactone had previously waned as a consequence of concerns over potential carcinogenicity and

an adverse effect profile which included antiandrogenic effects which could be problematic for male

patients, especially when the drug was used at the higher doses required in liver disease.

The literature supporting the role of spironolactone in paediatric heart failure is however limited. One

study in heart failure reported that it enhances the effect of digoxin and thiazide diuretics (61). The

second (62), in a paediatric population with heart, lung and other pathologies, reported that

spironolactone can be added to loop and/or thiazide diuretics, although it highlighted the need for

close monitoring of potassium levels and recommended that further research is needed to look at

pharmacokinetics and the most appropriate dosing interval in children.

Eplerenone is a newer, more specific aldosterone antagonist which has been studied in the post MI

setting in adults and has been shown to reduce the onset of heart failure in this setting (63). It has also

been used in patients requiring an aldosterone antagonist who are intolerant to spironolactone. There

is no published evidence on the role of eplerenone in the management of paediatric heart failure. One

review commented that eplerenone is one of the few newer drugs for which paediatric dosing has

been established (64), although it should be noted that this refers to the manufacturers data on file

rather than published studies.

Spironolactone is already included in the EMLc and although the available evidence specifically in

paediatrics is modest, it remains appropriate for it to be retained. In the absence of any clearadvantages for eplerenone from adult studies and the lack of published data on its use in children, it is

not considered appropriate to include this in the EMLc at the current time.

Betablockers

Rationale for use of betablockers:

Betablockers counter the activation of the sympathetic nervous system which is often seen in heart failure. The

beneficial effects of betablockers in heart failure may therefore include:

Slowed heart rate, improving balance of oxygen supply and demand Reduced myocardial apoptosis and fibrosis Antiarrhythmic effects Synergism with ACE inhibitors

A number of betablockers have been studied in large randomised trials in the management of cardiac

failure in adults, with generally consistent findings of reduced symptoms, morbidity and mortality. Of

those studied, bisoprolol (65, 66), carvedilol (67, 68), metoprolol (69) and, most recently, nebivolol (70)

Page12of31


13/31

have the greatest weight of evidence and are the most widely used in clinical practice in adult heart

failure.

Although the adult data for bucindolol is less favourable than that for other betablockers in terms of

outcome data (89), findings from the research with this agent may have significance for paediatrics,

given the recurrent concern about applying adult data to paediatrics where the aetiology is usually

different. One of the bucindolol trials in adults included patients with cardiomyopathy, a major causeof heart failure in children and the benefits of betablocker treatment were significant in this group

(90).

One study in adults directly compared carvedilol and metoprolol and indicated superior effects from

carvedilol (71), although it has been suggested that the formulation of metoprolol used in this study

may have contributed to these findings; otherwise, there is no data from which firm conclusions about

the specific advantages of one betablocker over another can be drawn.

In children with heart failure and related conditions, carvedilol has been the most widely studied

betablocker. Table 2 summarises the studies carried out to date. Beyond these studies, experience has

been gained with betablockers in children with a variety of other conditions, such as migraine.

However, few of these have much significance for the management of heart failure, with the possibleexception of a recent evaluation of metoprolol as an antihypertensive in children (72). No published

data on the use of nebivolol in children with heart failure was identified.

Reviews have commented that children with severe CHF who are started on beta blockers are

unlikely to tolerate the reduction in sympathetic drive (23), although this observation may be less

relevant to those with earlier stage disease. Concern has also been raised that whilst betablocker

therapy in adults reduces sudden cardiac death, the effect of betablockade in children does not

appear to reduce the QT interval in the same way (91), the significance of this is not yet known.

In addition to the studies shown in Table.2, other work has assessed the systemic exposure to

carvedilol amongst paediatric heart failure patients and has indicated that higher doses relative tobody weight are required to provide exposure comparable to adults. It was suggested that paediatric

carvedilol doses should subsequently be: 1mg/kg/day for adolescents, 2mg/kg/day for children aged 2

to 11 years and 3mg/kg/day for infants (aged 28 days to 23 months) (73). It should be noted that the

doses of carvedilol used in many of the studies summarised in Table.2 have been lower than these

recommendations, in some cases significantly lower.

The recently published randomised trial with carvedilol (74) has prompted significant debate and

comment. The authors and subsequent reviews have commented that these findings may have been

due to an unexpected level of improvement in the placebo arm, the low dose of carvedilol used and

the study being underpowered (7577). It has been suggested that, on this basis, the findings of this

trial may not mean there is no role for betablockers in this population (76) and that it is likely betablockers will continue to be used based on the evidence from adults (75).There is currently no betablocker included on the EMLc; based on the evidence and current clinical

opinion, this needs to be addressed. Although a number of betablockers have been studied in heart

failure, the greatest weight of evidence is with carvedilol both in adults and paediatrics; it is therefore

considered appropriate to recommend this betablocker is added to the EMLc.

Page13of31


14/31

Table 2. Summary of studies on betablockers in Paediatric Cardiac Failure and related conditions

(DCM=dilated cardiomyopathy, LVD=left ventricular dysfunction, VSD=ventricular septal defect)


with betablocker

Betablocker used Key findings and comments

(78)

Retrospective

46 with

cardiomyopathy or

congenital heart

disease

Carvedilol

(mean 0.46mg/kg)

Three month followup showed 67% of patients had improved NYHA class. 54%

had side effects, mainly dizziness, hypotension and headache which were generally

tolerated. Adverse outcomes (death, transplantation and ventricularassist device)

were reported in 30% of patients. Improvements were sustained in 25 children who

continued therapy for 12 months.

(79)Placebo

controlled

doubleblind

RCT

14 with HF awaitingtransplant

Carvedilol(0.2mg/kg/day)

Nine were removed from transplant list with improvements in LVEF and NHYAclass, four died and one underwent transplant. Amongst the 8 receiving placebo,

two died, two were transplanted and there was no significant improvement in

LVEF.

(80)

Open label

prospective

15 with DCM and

congenital heart

disease

Carvedilol

(0.7mg/kg/day)

Evaluated effect amongst those not responsive to standard therapy including

digoxin, diuretic and ACE inhibitor. In this study all patients achieved target dose

and at six month followup significant improvement in Ross Score and ejection

fraction was reported.

(81)

Retrospective

23 with DCM

congenital heart

disease, anthracycline

induced cardiac

damage

Carvedilol

(median maximum

0.9mg/kg/day

Assessed effect in children on treatment with ACE inhibitors, diuretics,

spironolactone and digoxin. This reported improvements in ejection fraction and

allowed 3 patients to be removed from transplant list. Benefits were most significant

in those who started carvedilol at an early age.

(82)

Retrospective

24 with DCM Carvedilol

(mean 0.98mg/kg/day)

Another study where added to therapy with ACE inhibitor, digoxin and diuretic. 22

patients continued for 2 years, with 15 patients (68%) had improvement in theNYHA class; there was one death and three required transplant. Adverse effects

occurred in 5 patients (21%) and carvedilol was stopped in 2 patients (8%).

(83). 20 with DCM and

congenital heart

disease

Carvedilol

(max 0.8mg/kg/day)

Significant improvement in ejection fraction amongst those with DCM treated for 6

months, with a trend towards delay in need for transplant and death. Carvedilol

was stopped in three patients during the study.

(74).

Placebo

controlled

doubleblind

RCT

103 with ventricular

systolic dysfunction

Carvedilol

(max. 0.4mg/kg)

Carvedilol patients randomised to one of two arms, one receiving 0.2mg/kg and the

other 0.4mg/kg. Of all those on carvedilol, 58 improved (56%), 25 worsened (24%)

and 20 were unchanged (19%), this was not significantly different to those on

placebo.


15/31

Page15of31


with betablocker

Betablocker used Key findings and comments

(84). 3 with doxorubicin

cardiomyopathy

Metoprolol

(max 2575mg bd)

Improved NYHA class and ejection fraction in all patients and enabled two of three

patients to be removed from transplantation waiting lists.

(85) 15 with DCM Metoprolol

(max 2.3mg/kg/day)

Improvements in systolic ventricular function followed the addition of metoprolol

to long standing conventional therapy with diuretics, digoxin and ACE inhibitor.

(86) 11 with Duchennes

cardiomyopathy

Metoprolol and

Bisoprolol

Reported improvements in symptoms and ventricular function after 6 months

therapy, effects sustained for 2 to 5 years.

(87) 6 with lefttoright

shunts

Propranolol

(max 3mg/kg/day)

Added to existing therapy with diuretics and digoxin, improvements in heart failure

score noted, reduced aldosterone and renin levels, 5 of 6 patients stopped diuretics.

(88) 10 with lefttoright

shunts

Propranolol

(max 2mg/kg/day)

Added to existing therapy with diuretics and digoxin, compared to control patients

those receiving propranolol had improvements in heart failure scores and reduced

aldosterone and renin levels.


16/31

Antiarrhythmic Medication

Rationale for use of antiarrhythmic medication:

Antiarrhythmic medication can reduce the incidence of cardiac arrhythmias and may potentially be useful in

heart failure where ventricular tachyarrhythmias are a major cause of mortality

Arrhythmias are a major cause of mortality and morbidity in children with cardiac failure (92). Over

half of children with dilated cardiomyopathy who die have ventricular arrhythmias at the time of

presentation and almost twothirds of those awaiting transplantation have lifethreatening

arrhythmias (93, 94).

Antiarrhythmic medication has been used in children, although there is a lack of trial data looking at

its role in paediatric cardiac failure. As with many other therapy options, there has been extrapolation

from studies in adults. In addition, there are risks associated with some antiarrhythmic medications,

in that they may have negative inotropic effects or have proarrhythmic effects. Two studies showed

that Class 1c antiarrhythmic drugs increased mortality, the first in paediatrics with structural heartdisease (95) and the second in adults postmyocardial infarction (96).

The role of betablockers in cardiac failure has been discussed elsewhere and it is likely that some of

the benefits reported are likely to be due to antiarrhythmic properties. The specific antiarrhythmic

properties of sotalol have been studied in children, with some success, but with side effects affecting

2030% of patients (97).

Amiodarone has been studied in children and whilst some studies suggested it was well tolerated

(98), others have raised concerns that the intravenous formulation may be linked with hypotension or

collapse (99).

Alternative approaches to the management of rhythm problems in children with heart failure have

been evaluated and paediatric electrophysiology has the potential to provide beneficial effects with or

without adjunctive drug therapy (92).

Given the limited role for antiarrhythmics in heart failure and lack of studies in children showing

beneficial outcomes, the inclusion of an antiarrhythmic to the EMLc is not considered appropriate.

Inotropes

Rationale for use of inotropes:

In severe heart failure, where cardiac output and blood pressure are low, inotropic drugs which stimulate

cardiac contractility and/or produce peripheral vascoconstriction have been used to try and maintain tissue

perfusion.

Management of the acute phase of cardiac failure has seen the use of inotropic (also referred to as

inodilator) drugs to maintain perfusion of vital organs, and the existing EMLc includes dopamine on

the supplementary list to fulfill this role.


17/31

A number of inotropes have been used in acute cardiac failure; amongst these are the catecholamines,

dopamine and dobutamine, and the phosphodiesterase inhibitors, milrinone and amrinone.

It is recognised that acute cardiac failure is often complicated by deterioration in renal function that is

associated with worsened outcomes and it has been suggested that this cardiorenal syndrome occurs

in children (100). The application of dopamine in acute heart failure also aims to address this

decreased renal function and evidence suggests that it is effective in achieving this in adults, althoughit is considered that further evaluation is needed (101).

In some situations, more than one inotrope has been given concomitantly, in an attempt to optimise

the specific effects of the individual drugs. However, data from adults suggests that use of more than

one inotrope in acute heart failure is associated with increased mortality (102).

The appropriateness of all inotropes in acute cardiac failure is controversial, based on the lack of

robust evidence and lack of alternative options (103). Two recent reviews have advised that there is a

limited role for inotropes in adults. One suggested that the use of inotropes should be restricted to

patients who, despite a high left ventricular filling pressure, remain hypotensive (103). The second,

that routine use in the acute setting is not indicated, but that there may be a role in those with

hypoperfusion or shock and in those awaiting transplant or revascularisation (104).

In common with the chronic management of cardiac failure, many of the studies in the acute phase

have been carried out in adults and the significance of their findings for children is unclear. In

children, the catecholamines have been the drugs of choice, with their pharmacokinetics permitting

titration to response and it is with dopamine that there is the greatest experience (105). The alternative

phosphodiesterase inhibitors produce significant pulmonary vasodilation and have little effect on

myocardial oxygen demand. Of the two available, milrinone is favoured on the basis of its shorter

halflife and wider therapeutic index (105).

Children with acute cardiac failure generally fall into one of two groups, those with established

cardiomyopathy and those who were previously healthy (106). In the former group, the acute phasemay present where the patient has become refractory to existing treatment or when precipitated by co morbid conditions such as anaemia or overwhelming infection. It is in situations such as these where

inotropic support has been utilised. In the case of those patients with exacerbations, treatment of the

underlying cause, where possible, should determine that the need for inotropic support is shortterm.

In the case of children refractory to existing treatment, the options for long term treatment may be

limited and are likely to include consideration for cardiac transplantation. Proceeding to transplant

immediately will however often not be possible or appropriate, due to the instability of the patient,

access to a transplant unit or availability of a suitable donor. Consequently, there may be a

requirement for the use of additional supportive treatments for a period of several months. In this

situation, inotropes have been used as a so called bridgingtherapy, which has been delivered inboth the inpatient and outpatient settings.

In one report, seven children with advanced chronic heart failure were given parenteral inotropic

therapy (mean 10 weeks), in the outpatient setting. Six patients were successfully bridged to

transplantation and one died. During the period of treatment, inotropes led to symptomatic

improvements and reductions in hospital admissions and presentations at the emergency department

(107).

Page17of31


18/31

In another similar study, 21 children awaiting transplant were given inotrope therapy (dobutamine,

milrinone or dopamine) at home. Survival at 12 months was reported as 84%, with improved cardiac

and renal function, and reduced hospitalisations (108).

A recent study has shown that amongst paediatric patients with acute heart failure due to

cardiomyopathy or myocarditis, up to 96% will recover over a two year period, during which time

they will require a package of intensive support, which includes inotropes and extracorporealmembrane oxygenation (109).

It should also be recognised that the use of nonpharmacological interventions has a significant and

increasing role in the management of acute cardiac failure in children (110).

Based on the available adult data and the absence of paediatric evidence, the routine use of inotropes

in acute cardiac failure in children cannot be recommended. In other scenarios, such as use shortterm

alongside treatment of exacerbating conditions and as a bridging therapy pending transplantation, it

would appear appropriate to include an inotrope on the EMLc. In the absence of compelling evidence

for change, it is suggested that the EMLc retains dopamine, as it possesses both the cardiac and renal

effects that are useful in this clinical situation.

Other therapies

Rationale for use of other medication:

Continued burden of cardiac failure with significant morbidity and mortality despite the existing treatment

options

A number of other therapies are under evaluation in the management of cardiac failure, many of these

in the acute phase of the condition.

Natriuretic peptides: Nesiritide is a recombinant Btype natriuretic peptide approved for use in somenations for the treatment of decompensated heart failure in adults.

Three studies have evaluated the role of nesiritide in children with heart failure in an intensive care

setting and have reported improvements in renal function and increased urine output (111113). The

authors of these studies and a further review (114) have all concluded that further work is needed to

assess the role of nesiritide.

The strength of the evidence available to date does not warrant the inclusion of nesiritide in the EMLc

for the routine management of cardiac failure in children at the current time.

Calcium sensitisers: Levosimendan is the first of this group to be evaluated. One study in children

with severe heart failure refractory to dobutamine, showed encouraging signs in terms of ejectionfraction, reduction discontinuation of catecholamine therapy and adverse effects (115). There are a

number of other reports on beneficial effects in individual patients; however, a recent review

commented that further experience and data is required (64).

On this basis, levosimendan is not considered appropriate for inclusion in the EMLc for the routine

management of cardiac failure in children at the current time.

Page18of31


19/31

Endothelin receptor antagonists: A number of these, including bosentan, tezosentan, darusentan and

sitaxsentan, have been developed and studied in a range of conditions, including pulmonary

hypertension and heart failure. Evidence of efficacy to date is variable and there are concerns about

the hepatotoxicity of bosentan. There is no data on efficacy or safety in children. Depending on

findings, the ongoing work in adult populations may give rise to paediatric studies in due course (64).

Roles for endothelin receptor antagonists remain to be clarified and there is no place for these drugs inthe EMLc for the routine management of cardiac failure in children at the current time.

Discussion

Treatment

Clinical practice in the management of cardiac failure in children currently uses some or all of the

following drug treatments: diuretics, digoxin, spironolactone, ACE inhibitors, betablockers and

inotropes.

There are no national or international guidelines on the management of cardiac failure in children

and, consequently, the approach to treatment is based on a combination of clinical experience amongstthose involved in management, application of findings from many studies in adults with cardiac

failure and the modest data from studies in children.

The data from studies in children is suboptimal and when considered in isolation provides a poor

basis for making decisions and wider recommendations. There are several reasons for this, including

the small size of many studies, reliance on retrospective studies, the variation in causes of cardiac

failure and age range amongst study participants, the doses of drugs used and variation in measures

used to assess outcomes.

There is, however, reasonable evidence that some children with cardiac failure do benefit from

treatment with drugs which have a proven evidence base in adults, in particular ACE inhibitors and

betablockers.

Unanswered Questions

In compiling this report there are a number of recurrent themes which require consideration when

developing the EMLc and guidelines on the management of cardiac failure in children. These fall into

four main areas.

Paediatric practice based on adult evidence

Although the available paediatrics literature provides grounds for optimism in the use of drug

therapy for cardiac failure, there remain questions about clinical practice in children being

driven primarily by studies carried out in adults, where the underlying pathology of paediatricheart failure is significantly different.

Specific drug issues

Questions have been asked about the metabolic and electrolytic effects of loop diuretics, which

may have potentially deleterious effects on the underlying pathology of heart failure.

However, given that the presentation of cardiac failure is associated with oedema, which

Page19of31


20/31

invariably responds rapidly and significantly to diuretics, resolving these issues will be

challenging.

The role of digoxin also remains somewhat unclear, based on the lack of robust evidence.

Dosage

The literature provides ample evidence of a wide disparity of dosing regimens being used in

paediatric practice and it needs to be considered that these may have had significant effects on

the outcome of some of the studies referred to. There is a need for further evaluation of the

pharmacokinetics of many drugs used in heart failure in children to confirm both the dose and

dosing interval that is required for optimal clinical benefit.

Use of products outside of license

In common with many other areas of paediatric clinical practice, the management of heart

failure currently uses unlicensed drugs and licensed drugs outside of their product license.

There are several inherent problems associated with this.

To obtain a marketing authorisation to treat a specific condition in a specific patientgroup, the manufacturer is required to submit data to the licensing authorities to

support claims of efficacy and an acceptable balance of risks and benefits.

Consequently, when using an unlicensed drug or a licensed drug outside of its license,

healthcare professionals and patients/carers are required to formulate their own

judgments as to appropriateness based on suboptimal information.

Prescribers and others involved in the delivery of unlicensed drugs or licensed drugsoutside of their license to the patient, carry greater legal responsibilities should harm be

caused, than would be the case if prescribing was of a licensed product within the

terms of its license.

Unlicensed products are not as readily available as licensed products, which canintroduce barriers to the timely delivery of medication to patients.

Unlicensed products are not required to conform to the same consistent standards ofmanufacture as licensed products and there may be greater variation in the

bioavailability of the active ingredient between different unlicensed formulations than

there would be between different licensed formulations for the same drug.

In an ideal situation, all the drugs which are required would be licensed for use in children for

the management of cardiac failure and be available in formulations which were appropriate

for administration to children at the doses required. It has been suggested that where the

required drugs are not available as licensed products, they should not be used and that greater

pressure should be exerted on manufacturers and other organisations to invest in the research

necessary to show the effectiveness (or otherwise) of the drugs involved, thus establishing the

evidence base necessary to enable license applications to be made. This, however, would create

a dilemma in that children would continue to present with heart failure whilst this research

was undertaken and those outside of the trials would be denied treatments which, based on

the limited data available already, may have had a significant probability of improving their

outcome.

Page20of31


21/31

There is without doubt a need for a greater evidence base in the management of cardiac failure

in children and the development of this through research should be encouraged. In the

meantime the risks associated with the use of unlicensed and off label medications could be

reduced by the requirement for greater standardisation in their manufacture to provide

patients, carers and healthcare professionals greater confidence in their stability and

bioavailability. The development of a prescribing reference to guide the appropriate off label

use of medication in children would also assist in reducing the risks associated with this

necessary practice. The WHO should give consideration to these two areas as medium and

shortterm priorities, to improve the management of heart failure in children.

Conclusion

The last twenty years have witnessed a significant advance in the evidence for and availability of drug

therapies which can have a huge impact on the outcome for adult patients with heart failure. The

situation with paediatric cardiac failure has followed a similar pattern, but has tended to be based on

less robust evidence.

There is a compelling need for larger and higher quality studies on the drug treatment of cardiac

failure in children to provide a more robust evidence base from which practice can develop.

Alongside this is the need for greater availability and standardisation of products and formulations

suitable for administration to children.

In the meantime, there is sufficient experience and evidence on which to base provisional

recommendations affecting the EMLc. These would be for the addition of an ACE inhibitor and betablocker to the EMLc, (refer to accompanying applications for inclusion) to be used alongside those

therapy options already included in the EMLc: frusemide, digoxin, spironolactone and dopamine,

where they are clinically indicated.

Page21of31


22/31

Appendix 1:SearchStrategySearches Performed

Initial:

Reviewed current EMLc

Searched WHO website

Reviewed EMEA Assessment of the paediatric needs Cardiovascular products, Oct 06British National Formulary for Children, BMA / RPSGB / RCPCH, London, 2008

The Paediatric Cardiology Pharmacopeia, 2004 Update

PubMed:

Cardiac failure (title) AND Children (any field); Review 16 found

Heart failure (title) AND Children (any field); Review 65 found: looked at 2000+ only

Heart failure (title) AND paediatrics OR pediatrics (any field); Review; 20002008 22 found

Cardiac failure (title) AND paediatrics OR pediatrics (any field); Review; 2000 2008 3 found

Heart failure (title) AND Children (Title); 20002008 65 found

Heart failure (title) AND Children (Title) AND epidemiology (any field); 20052008 5 found

Heart failure (title) AND paediatrics OR pediatrics (title); AND epidemiology (any field); 20052008 0 found

Cardiac failure (title) AND Children (Title) AND epidemiology (any field); 20052008 1 found

Cardiac failure (title) AND paediatrics OR pediatrics (title); AND epidemiology (any field); 20052008 0 found

Heart failure (title) AND Children (any field) AND epidemiology (any field); 20052008 21 found

Heart failure (title) AND paediatrics OR pediatrics (any field); AND epidemiology (any field); 20052008 13

found

Cardiac failure (title) AND Children (any field) AND epidemiology (any field); 20052008 6 found

Cardiac failure (title) AND paediatrics OR pediatrics (any field); AND epidemiology (any field); 20052008 4

found

Heart failure (title) AND Children (any field) AND burden (any field); 20052008 3 found

Heart failure (title) AND paediatrics OR pediatrics (any field); AND burden (any field); 2005 2008 1 found

Cardiac failure (title) AND Children (any field) AND burden (any field); 20052008 1 found

Cardiac failure (title) AND paediatrics OR pediatrics (any field); AND burden (any field); 20052008 1 found

Heart failure (title) AND Children (any field) AND management (any field); 20052008 25 foundHeart failure (title) AND paediatrics OR pediatrics (any field); AND management (any field); 2005 2008 20

found

Cardiac failure (title) AND Children (any field) AND management (any field); 20052008 4 found

Cardiac failure (title) AND paediatrics OR pediatrics (any field); AND management (any field); 20052008 5

found

Heart failure (title) AND Children (any field) AND treatment (any field); 20052008 75 found

Heart failure (title) AND paediatrics OR pediatrics (any field); AND treatment (any field); 20052008 58 found

Cardiac failure (title) AND Children (any field) AND treatment (any field); 20052008 24 found

Cardiac failure (title) AND paediatrics OR pediatrics (any field); AND treatment (any field); 20052008 13

found

Cardiac failure (title) AND Children (any field) AND incidence (any field); 19952008 21 foundCardiac failure (title) AND paediatrics OR pediatrics (any field); AND incidence (any field); 20052008 0 found

Heart failure (title) AND Children (any field) AND incidence (any field); 20052008 65 found

Heart failure (title) AND paediatrics OR pediatrics (any field); AND incidence (any field); 2005 2008 2 found

Heart failure (title) AND children (any field) AND diuretic (any field); 19952008 4 found

Heart failure (title) AND pediatric (any field) AND diuretic (any field); 19952008 4 found

Cardiac failure (title) AND children (any field) AND diuretic (any field); 19952008 0 found

Cardiac failure (title) AND pediatric (any field) AND diuretic (any field); 19952008 0 found

Heart failure (title) AND children (any field) AND ACE inhibitor (any field); 19952008 1 found

Page22of31


23/31

Heart failure (title) AND pediatric (any field) AND ACE inhibitor (any field); 19952008 2 found

Cardiac failure (title) AND children (any field) AND ACE inhibitor (any field); 19952008 0 found

Cardiac failure (title) AND pediatric (any field) AND ACE inhibitor (any field); 19952008 0 found

Heart failure (title) AND children (any field) AND betablocker (any field); 19952008 8 found

Heart failure (title) AND pediatric (any field) AND betablocker (any field); 19952008 6 found

Cardiac failure (title) AND children (any field) AND betablocker (any field); 19952008 0 found

Cardiac failure (title) AND pediatric (any field) AND betablocker (any field); 19952008 0 foundHeart failure (title) AND children (any field) AND digoxin (any field); 19952008 17 found

Heart failure (title) AND pediatric (any field) AND digoxin (any field); 19952008 14 found

Cardiac failure (title) AND children (any field) AND digoxin (any field); 19952008 0 found

Cardiac failure (title) AND pediatric (any field) AND digoxin (any field); 19952008 0 found

Heart failure (title) AND children (any field) AND spironolactone (any field); 19952008 2 found

Heart failure (title) AND pediatric (any field) AND spironolactone (any field); 19952008 1 found

Cardiac failure (title) AND children (any field) AND spironolactone (any field); 19952008 0 found

Cardiac failure (title) AND pediatric (any field) AND spironolactone (any field); 19952008 0 found

Acute heart failure (title) AND children (any field); 19952008 23 found

Acute cardiac failure (title) AND children (any field); 19952008 6 found

Acute heart failure (title) AND pediatric (any field); 19952008 17 found

Acute cardiac failure (title) AND pediatric (any field); 19952008 4 found

Heart failure (title) AND dopamine (any field); 19952008 127 found

Heart failure (title) AND dobutamine (any field); 19952008 333 found

Children (title) AND dopamine (any field); 19952008 273 found

Pediatric (title) AND dopamine (any field); 19952008 55 found

Children (title) AND dobutamine (any field); 19952008 37 found

Pediatric (title) AND dobutamine (any field); 19952008 23 found

Children (title) AND milrinone (any field); 19952008 12 found

Pediatric (title) AND milrinone (any field); 19952008 11 found

Heart failure (title) AND children (any field) AND inotropic (any field); 19952008 11 found

Cardiac failure (title) AND children (any field) AND inotropic (any field); 19952008 1 found

Heart failure (title) AND pediatric (any field) AND inotropic (any field); 19952008 12 foundCardiac failure (title) AND pediatric (any field) AND inotropic (any field); 19952008 1 found

Heart failure (title) AND children (any field) AND dopamine (any field); 19952008 6 found

Cardiac failure (title) AND children (any field) AND dopamine (any field); 19952008 0 found

Heart failure (title) AND pediatric (any field) AND dopamine (any field); 19952008 5 found

Cardiac failure (title) AND pediatric (any field) AND dopamine (any field); 19952008 1 found

Heart failure (title) AND children (any field) AND dobutamine (any field); 19952008 3 found

Cardiac failure (title) AND children (any field) AND dobutamine (any field); 19952008 1 found

Heart failure (title) AND pediatric (any field) AND dobutamine (any field); 19952008 8 found

Cardiac failure (title) AND pediatric (any field) AND dobutamine (any field); 19952008 2 found

Heart failure (title) AND children (any field) AND nesiritide (any field); 19952008 3 found

Cardiac failure (title) AND children (any field) AND nesiritide (any field); 19952008 0 found

Cochrane Library:

Cardiac failure; no other limits 25 items found

Heart failure; no other limits 64 items found

Children cardiac failure; no other limits 4 items found

Children heart failure; no other limits 5 items found

Pediatric cardiac failure; no other limits 18 items found

Pediatric heart failure; no other limits 5 items found

Page23of31


24/31

BMJ Clinical Evidence





Pediatric cardiac failure; no other limits 2 items foundPaediatric cardiac failure; no other limits 3 items found


Paediatric heart failure; no other limits 2 items found

National Guideline Clearinghouse





Pediatric cardiac failure; no other limits 67 items found

Paediatric cardiac failure; no other limits 17 items found


Paediatric heart failure; no other limits 14 items found

Page24of31


25/31

References

1. Aurora P, Boucek MM, Christie J, Dobbels F, Edwards LB, Keck BM, et al. Registry of the International

Society for Heart and Lung Transplantation: tenth official pediatric lung and heart/lung transplantation

report2007. J Heart Lung Transplant. 2007 Dec;26(12):12238.

2. Amoah AG, Kallen C. Aetiology of heart failure as seen from a National Cardiac Referral Centre in Africa.

Cardiology. 2000;93(12):118.

3. Venugopalan P, Agarwal AK, Akinbami FO, El Nour IB, Subramanyan R. Improved prognosis of heart

failure due to idiopathic dilated cardiomyopathy in children. Int J Cardiol. 1998 Jul 1;65(2):1258.

4. Adekanmbi AF, Ogunlesi TA, Olowu AO, Fetuga MB. Current trends in the prevalence and aetiology of

childhood congestive cardiac failure in Sagamu. J Trop Pediatr. 2007 Apr;53(2):1036.

5. Maiya S, Sullivan I, Allgrove J, Yates R, Malone M, Brain C, et al. Hypocalcaemia and vitamin D

deficiency: an important, but preventable, cause of lifethreatening infant heart failure. Heart. 2008

May;94(5):5814.

6. Kay JD, Colan SD, Graham TP, Jr. Congestive heart failure in pediatric patients. Am Heart J. 2001

Nov;142(5):9238.

7. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric

cardiomyopathy in two regions of the United States. N Engl J Med. 2003 Apr 24;348(17):164755.

8. Nugent AW, Daubeney PE, Chondros P, Carlin JB, Cheung M, Wilkinson LC, et al. The epidemiology of

childhood cardiomyopathy in Australia. N Engl J Med. 2003 Apr 24;348(17):163946.

9. Andrews RE, Fenton MJ, Ridout DA, Burch M. Newonset heart failure due to heart muscle disease in

childhood: a prospective study in the United kingdom and Ireland. Circulation. 2008 Jan 1;117(1):7984.

10. Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela AL, et al. Epidemiology of idiopathic

cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol. 1997 Sep

1;146(5):38593.

11. Anon. NICE Guideline No.5. Chronic Heart Failure. London: National Institute for Clincal and Health

Excellence 2003 Contract No.: Document Number|.

12. Anon. Management of chronic heart failure. Guideline No. 95: Scottish Intercollegiate Guidelines

Network; 2007 Contract No.: Document Number|.

13. Hunt SA AW, Chin MH FA, Francis GS, Ganiats TG, Jessup M, Konstam MA,, Mancini DM MK, Oates JA,

Rahko PS, Silver MA, Stevenson LW, Yancy, Site. CACoCW,

http://www.acc.org/clinical/guidelines/failure//index.pdf . 2005 guideline update for the diagnosis and

management of chronic heart failure in the adult: a report of the American College of

Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update

the 2001 Guidelines for the Evaluation and Management of Heart Failure). . Bethesda: ACC/AHA 2005

14. Swedberg K, Cleland JG, Dargie H, al. E. Guidelines for the diagnosis and treatment of Chronic Heart

Failure: full text (update 2005): European Society of Cardiology; 2005 Contract No.: Document Number|.

15. Krum H JM, Stewart S, Sindone A, Atherton J, Hawkes A on behalf of, . tCHFCPGEWP. Guidelines for the

Prevention, Detection and Management of

People with Chronic Heart Failure in Australia, 2006. 2006(National Heart Foundation of Australia and the

Cardiac Society of Australia

and New Zealand ).

Page25of31
http://www.acc.org/clinical/guidelines/failure/index.pdfhttp://www.acc.org/clinical/guidelines/failure/index.pdfhttp://www.acc.org/clinical/guidelines/failure/index.pdfhttp://www.acc.org/clinical/guidelines/failure/index.pdf


26/31

16. Hoch M, Netz H. Heart failure in pediatric patients. Thorac Cardiovasc Surg. 2005 Feb;53 Suppl 2:S12934.

17. Balaguru D, Artman M, Auslender M. Management of heart failure in children. Curr Probl Pediatr. 2000

Jan;30(1):135.

18. Shaddy RE. Optimizing treatment for chronic congestive heart failure in children. Crit Care Med. 2001

Oct;29(10 Suppl):S23740.

19. Burch M. Heart failure in the young. Heart. 2002 Aug;88(2):198202.

20. Balfour I. Management of Chronic Congestive Heart Failure in Children. Curr Treat Options Cardiovasc

Med. 2004 Oct;6(5):40716.

21. Margossian R. Contemporary management of pediatric heart failure. Expert Rev Cardiovasc Ther. 2008

Feb;6(2):18797.

22. Odland HH, Thaulow EM. Heart failure therapy in children. Expert Rev Cardiovasc Ther. 2006Jan;4(1):3340.

23. Fenton M, Burch M. Understanding chronic heart failure. Arch Dis Child. 2007 Sep;92(9):8126.

24. Mulla H, Tofeig M, BuLock F, Samani N, Pandya HC. Variations in captopril formulations used to treat

children with heart failure: a survey in the United Kingdom. Arch Dis Child. 2007 May;92(5):40911.25. Weber KT. Furosemide in the longterm management of heart failure: the good, the bad, and the

uncertain. J Am Coll Cardiol. 2004 Sep 15;44(6):130810.

26. Faris R FM, Purcell H, PooleWilson PS, Coats AJS. Diuretics for heart failure. Cochrane Database of

Systematic Reviews. 2006.

27. Ward OC, Lam LK. Bumetanide in heart failure in infancy. Arch Dis Child. 1977 Nov;52(11):87782.

28. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic

heart failure NYHA II to IVefficacy and quality of life. Eur J Heart Fail. 2003 Dec;5(6):793801.

29. Senzaki H, Kamiyama MP, Masutani S, Ishido H, Taketazu M, Kobayashi T, et al. Efficacy and safety of

Torasemide in children with heart failure. Arch Dis Child. 2008 Mar 12.30. Lowrie L. Diuretic therapy of heart failure in infants and children. Prog Pediatr Cardiol. 2000 Nov

4;12(1):4555.

31. Arnold WC. Efficacy of metolazone and furosemide in children with furosemideresistant edema.

Pediatrics. 1984 Nov;74(5):8725.

32. Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR. Combination therapy with metolazone and loop

diuretics in outpatients with refractory heart failure: an observational study and review of the literature.

Cardiovasc Drugs Ther. 2005 Aug;19(4):3016.

33. Anon. Assessment of the paediatric needs cardiovascular products. London: European Medicines Agency;

2006 October 2006 Contract No.: Document Number|.

34. Hood WB DA, Guyall GH, Jaeschke R, McMurray JJV. Digitalis for treatment of congestive cardiac failure

in patients in sinus rhythm. Cochrane Database of Systematic Reviews. 2004.

35. Ratnapalan S, Griffiths K, Costei AM, Benson L, Koren G. Digoxincarvedilol interactions in children. J

Pediatr. 2003 May;142(5):5724.

36. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death

among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the

AIRE Study Investigators. Eur Heart J. 1997 Jan;18(1):4151.

Page26of31


27/31

37. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular

events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol

adding bendroflumethiazide as required, in the AngloScandinavian Cardiac Outcomes TrialBlood

Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 1016;366(9489):895906.

38. The Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT). Major

outcomes in highrisk hypertensive patients randomised to angiotensinconverting enzyme inhibitor orcalcium channel blocker vs diuretic. JAMA. 2002;288:298197.

39. Randomised trial of a perindoprilbasedbloodpressurelowering regimen among 6,105 individuals with

previous stroke or transient ischaemic attack. Lancet. 2001 Sep 29;358(9287):103341.

40. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in

type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12;317(7160):71320.

41. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and

nondiabetic chronic renal disease: a systematic overview of randomized placebocontrolled trials. Am J

Kidney Dis. 2000 Apr;35(4):695707.

42. Seeman T, Gilik J, Vondrak K, Simkova E, Flogelova H, Hladikova M, et al. Regression of leftventricular

hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J

Hypertens. 2007 Sep;20(9):9906.

43. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A doubleblind, placebocontrolled, doseresponse

study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003

Oct;16(10):795800.

44. Leversha AM, Wilson NJ, Clarkson PM, Calder AL, Ramage MC, Neutze JM. Efficacy and dosage of

enalapril in congenital and acquired heart disease. Arch Dis Child. 1994 Jan;70(1):359.

45. Momma K. ACE inhibitors in pediatric patients with heart failure. Paediatr Drugs. 2006;8(1):5569.

46. Lewis AB, Chabot M. The effect of treatment with angiotensinconverting enzyme inhibitors on survival of

pediatric patients with dilated cardiomyopathy. Pediatr Cardiol. 1993 Jan;14(1):912.

47. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC, 2nd, Shaikh SL, Mone SM, et al. Longterm enalapril

therapy for left ventricular dysfunction in doxorubicintreated survivors of childhood cancer. J Clin Oncol.

2002 Dec 1;20(23):451722.

48. Stern H, Weil J, Genz T, Vogt W, Buhlmeyer K. Captopril in children with dilated cardiomyopathy: acute

and longterm effects in a prospective study of hemodynamic and hormonal effects. Pediatr Cardiol. 1990

Jan;11(1):228.

49. Eronen M, Pesonen E, Wallgren EI, Tikkanen I, Fyhrquist F, Andersson S. Enalapril in children with

congestive heart failure. Acta Paediatr Scand. 1991 May;80(5):5558.

50. Frenneaux M, Stewart RA, Newman CM, HallidieSmith KA. Enalapril for severe heart failure in infancy.

Arch Dis Child. 1989 Feb;64(2):21923.

51. Sluysmans T, StynsCailteux M, TremourouxWattiez M, de Lame PA, Lintermans J, Rubay J, et al.

Intravenous enalaprilat and oral enalapril in congestive heart failure secondary to ventricular septal defect

in infancy. Am J Cardiol. 1992 Oct 1;70(9):95962.

52. Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis

Child. 1988 Apr;63(4):3603.

Page27of31


28/31

53. Alehan D, Ozkutlu S. Beneficial effects of 1year captopril therapy in children with chronic aortic

regurgitation who have no symptoms. Am Heart J. 1998 Apr;135(4):598603.

54. Hazama K, Nakazawa M, Momma K. Effective dose and cardiovascular effects of cilazapril in children

with heart failure. Am J Cardiol. 2001 Oct 1;88(7):8015.

55. Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, et al. Effects of losartan and

captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular

function substudy. Am Heart J. 2000 Jun;139(6):10817.

56. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in

patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensinconvertingenzyme inhibitors: the CHARMAlternative trial. Lancet. 2003 Sep 6;362(9386):7726.

57. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart

failure. N Engl J Med. 2001 Dec 6;345(23):166775.

58. Sakarcan A, Tenney F, Wilson JT, Stewart JJ, Adcock KG, Wells TG, et al. The pharmacokinetics of

irbesartan in hypertensive children and adolescents. J Clin Pharmacol. 2001 Jul;41(7):7429.

59. Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. Adoubleblind,doseresponse study

of losartan in hypertensive children. Am J Hypertens. 2005 Feb;18(2 Pt 1):18390.

60. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on

morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study

Investigators. N Engl J Med. 1999 Sep 2;341(10):70917.

61. Hobbins SM, Fowler RS, Rowe RD, Korey AG. Spironolactone therapy in infants with congestive heart

failure secondary to congenital heart disease. Arch Dis Child. 1981 Dec;56(12):9348.

62. Buck ML. Clinical experience with spironolactone in pediatrics. Ann Pharmacother. 2005 May;39(5):8238.

63. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone

blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr

3;348(14):130921.

64. Moffett BS, Chang AC. Future pharmacologic agents for treatment of heart failure in children. Pediatr

Cardiol. 2006 SepOct;27(5):53351.

65. The Cardiac Insufficiency Bisoprolol Study II (CIBISII): a randomised trial. Lancet. 1999 Jan 2;353(9146):913.

66. A randomized trial of betablockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS).

CIBIS Investigators and Committees. Circulation. 1994 Oct;90(4):176573.

67. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in

severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):16518.

68. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the

morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized

cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):21949.

69. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in

Congestive Heart Failure (MERITHF). Lancet. 1999 Jun 12;353(9169):20017.

70. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial

to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients

with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):21525.

Page28of31


29/31

71. TorpPedersen C, PooleWilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, et al. Effects of

metoprolol and carvedilol on causespecific mortality and morbidity in patients with chronic heart failureCOMET. Am Heart J. 2005 Feb;149(2):3706.

72. Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, et al. Efficacy and safety of extended

release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J

Pediatr. 2007 Feb;150(2):1349, 9 e1.

73. Albers S, Meibohm B, Mir TS, Laer S. Population pharmacokinetics and dose simulation of carvedilol in

paediatric patients with congestive heart failure. Br J Clin Pharmacol. 2008 Apr;65(4):51122.

74. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and

adolescents with heart failure: a randomized controlled trial. JAMA. 2007 Sep 12;298(10):11719.

75. Foerster SR, Canter CE. Pediatric heart failure therapy with betaadrenoceptor antagonists. Paediatr

Drugs. 2008;10(2):12534.

76. Cotts T. Carvedilol of no clear benefit for systolic heart failure in children. J Pediatr. 2008Jan;152(1):1423.

77. Frobel AK HWM, Schmidt KG, OstmanSmith I, Laer S. Beta blockers for congestive heart failure in

children (protocol). Cochrane Database of Systematic Reviews. 2008.

78. Bruns LA, Chrisant MK, Lamour JM, Shaddy RE, Pahl E, Blume ED, et al. Carvedilol as therapy in

pediatric heart failure: an initial multicenter experience. J Pediatr. 2001 Apr;138(4):50511.

79. Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart

transplantation waiting list after carvedilol treatment. J Am Coll Cardiol. 2002 Dec 4;40(11):20348.

80. Laer S, Mir TS, Behn F, Eiselt M, Scholz H, Venzke A, et al. Carvedilol therapy in pediatric patients with

congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J. 2002

May;143(5):91622.

81. Lee KJ MB, Dipchand AI, Russell JL, Benson LN. Carvedilol in Heart Failure Management: A Paediatric

Experience. Canadian Journal of Cardiology. 2001;17 (Suppl.C):100C.

82. Rusconi P, GomezMarin O,RossiqueGonzalez M, Redha E, Marin JR, LonYoungM, et al. Carvedilol inchildren with cardiomyopathy: 3year experience at a single institution. J Heart Lung Transplant. 2004

Jul;23(7):8328.

83. Blume ED, Canter CE, Spicer R, Gauvreau K, Colan S, Jenkins KJ. Prospective singlearm protocol of

carvedilol in children with ventricular dysfunction. Pediatr Cardiol. 2006 MayJun;27(3):33642.

84. Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, et al. Efficacy and safety of

metoprolol in the treatment of doxorubicininduced cardiomyopathy in pediatric patients. Am Heart J.

1995 Jan;129(1):1979.

85. Shaddy RE, Tani LY, Gidding SS, Pahl E, Orsmond GS, Gilbert EM, et al. Betablocker treatment of dilated

cardiomyopathy wi

who paed cardiac failure review

Documents